Simmons & Simmons has advised on the AIM placing and subscription announced on 25 May 2017 by NetScientific plc, the transatlantic healthcare IP commercialisation group.

The team advised the nominated adviser and broker Stifel Nicolaus Europe Limited and placing agent Liberum on the placing and subscription of 17,916,662 new ordinary shares at 45 pence per share, raising a total of £8.1m for Netscientific (before expenses).

This is the latest in a series of transactions that the firm has advised on in the life sciences sector. The firm is recognised worldwide advising pharma, biotech, medical device, digital health and healthcare companies, including global pharmaceutical companies, fast growing biotechs, leading medical devices manufacturers, private and public healthcare establishments, and service providers and household names in consumer healthcare.

The UK team have most recently advised REX Bionics plc and Venture Life plc on their flotations and further deals as public companies, as well as JP Morgan on the record-breaking £581m Circassia IPO, Cenkos Securities on the £20m AIM IPO of Creo Medical Group, and Stifel on the £20m AIM IPO of Oxford BioDynamics.

Commenting on the transaction, partner Charles Mayo, said: "We were pleased to use our sector expertise advising Stifel and Liberum as they assisted NetScientific to raise finance in support of their strategy to fund and develop technology that offers transformative benefits to people with chronic disease".

The Simmons & Simmons team was led by Charles Mayo, assisted by Tim Wass, Phoebe So, Haya Aftab and Benjamin Tan